A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT07391657
Trial Phases:	Phase III	Protocol IDs:	D8311C00001 (primary) NCI-2026-01719 AZD0120
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT07391657

Summary

This is a randomised, multicentre, controlled, open-label, Phase III global study
comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab,
carfilzomib, and dexamethasone], DPd [daratumumab, pomalidomide, and dexamethasone], PVd
[pomalidomide, bortezomib and dexamethasone], or Kd [carfilzomib and dexamethasone]) in
participants with RRMM.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.